Utama › Kanser Payudara › California › Orange
Kajian klinikal Kanser Payudara di Orange, CA
14 kajian untuk Kanser Payudara sedang mencari peserta di lokasi dalam dan sekitar Orange (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Mengambil pesertaFasa 3
- UC Irvine Medical Center, Orange
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Mengambil pesertaFasa 1/2
- University of California Irvine, Orange
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Mengambil pesertaFasa 2
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Mengambil pesertaFasa 2
- Community Clinical Trials, Orange
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Mengambil pesertaFasa 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Mengambil pesertaFasa 3
- UC Irvine Health, Chao Family Comprehensive Cancer Center, Orange
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Mengambil pesertaFasa 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
E-Mindfulness Approaches for Living After Breast Cancer
Mengambil pesertaFasa 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Mengambil pesertaFasa 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Mengambil pesertaFasa 3
- Saint Joseph Hospital - Orange, Orange
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Mengambil pesertaFasa 2
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Mengambil pesertaFasa 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Orange
Kajian Kanser Payudara di bandar lain
- New York City, NY136 kajian
- Houston, TX126 kajian
- Boston, MA112 kajian
- Nashville, TN81 kajian
- Los Angeles, CA73 kajian
- Edison, NJ68 kajian
- St. Louis, MO64 kajian
- Queens, NY64 kajian
- Durham, NC64 kajian
- Chicago, IL59 kajian
- Philadelphia, PA56 kajian
- Dallas, TX55 kajian
Kajian lain di Orange
- Kanser Paru-paru Bukan Sel Kecil25 kajian
- Kanser Metastatik20 kajian
- Kanser Kolorektal16 kajian
- Kanser Ovari16 kajian
- Kanser Pankreas15 kajian
- Melanoma14 kajian
- Kanser Hati (Karsinoma Hepatoselular)14 kajian
- Kanser Paru-paru14 kajian
- Kanser Prostat14 kajian
- Kanser Perut13 kajian
- Kanser (semua jenis)13 kajian
- Leukemia Mieloid Akut13 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.